Moderna, Inc. $MRNA Shares Purchased by Korea Investment CORP

Key Points

• Korea Investment CORP increased its holdings in Moderna, Inc. by 8.4%, owning a total of 167,547 shares valued at approximately $4.75 million.
• Moderna's market capitalization stands at $10.55 billion, with its stock trading between a 12-month low of $23.15 and a high of $84.28.
• Analysts have mixed views on Moderna, with a consensus rating of "Hold" and a current consensus price target of $42.88.

Korea Investment CORP increased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 8.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 167,547 shares of the company's stock after purchasing an additional 13,000 shares during the period. Korea Investment CORP's holdings in Moderna were worth $4,750,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in MRNA. Voloridge Investment Management LLC raised its holdings in shares of Moderna by 335.6% during the fourth quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company's stock worth $107,727,000 after purchasing an additional 1,996,003 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Moderna by 17.5% during the first quarter. Invesco Ltd. now owns 5,883,624 shares of the company's stock worth $166,801,000 after purchasing an additional 877,162 shares during the last quarter. Nuveen LLC purchased a new position in shares of Moderna during the first quarter worth $19,510,000. Deutsche Bank AG raised its holdings in shares of Moderna by 54.7% during the fourth quarter. Deutsche Bank AG now owns 1,894,075 shares of the company's stock worth $78,756,000 after purchasing an additional 669,614 shares during the last quarter. Finally, TB Alternative Assets Ltd. purchased a new position in shares of Moderna during the first quarter worth $18,495,000. Hedge funds and other institutional investors own 75.33% of the company's stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Cowen assumed coverage on shares of Moderna in a report on Sunday, July 13th. They set a "hold" rating for the company. Leerink Partners dropped their price target on shares of Moderna from $18.00 to $15.00 and set an "underperform" rating on the stock in a research report on Friday, August 22nd. Wells Fargo & Company restated an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. William Blair restated a "market perform" rating on shares of Moderna in a research report on Monday, June 2nd. Finally, Evercore ISI set a $32.00 price target on shares of Moderna in a research report on Friday, August 1st. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, sixteen have given a Hold rating and four have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $42.88.

Moderna Stock Down 2.9%

Shares of NASDAQ MRNA traded down $0.72 during trading on Thursday, hitting $24.38. The company had a trading volume of 2,934,898 shares, compared to its average volume of 10,697,116. The stock has a fifty day simple moving average of $29.14 and a two-hundred day simple moving average of $28.94. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $79.96. The firm has a market capitalization of $9.49 billion, a price-to-earnings ratio of -3.23 and a beta of 1.83.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. The firm had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. Moderna's quarterly revenue was down 41.1% on a year-over-year basis. During the same period in the previous year, the business posted ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. On average, analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.